gms | German Medical Science

22nd Annual Meeting of the German Retina Society

German Retina Society

26.06. - 27.06.2009, Berlin

Early Effects of Triamcinolone Acetonide on Matrix Metalloproteinases and Endostatin in Human Choroidal Neovascularization

Meeting Abstract

  • Olcay Tatar - University Eye Clinic of Tuebingen
  • K. Shinoda - National Institute of Sensory Organs, Laboratory of Visual Physiology, Tokyo
  • E. Kaiserling - University Eye Clinic of Tuebingen, Institute for Pathology
  • B. Kirchhof - University Eye Clinic of Cologne
  • G. Scharioth - Eye Centre Recklinghausen
  • C. Eckardt - Clinic of Frankfurt-Hoechst, Eye Clinic
  • T. Eckert - Clinic of Frankfurt-Hoechst, Eye Clinic
  • K. Lucke - Eye Clinic Universitaetsallee, Bremen
  • S. Bopp - Eye Clinic Universitaetsallee, Bremen
  • G. Pertile - Sacro Cuore Hospital, Department of Ophthalmology, Negrar, Italy
  • E. Yoeruek - University Eye Clinic of Tuebingen
  • S. Grisanti - University Eye Clinic of Luebeck
  • K. U. Bartz-Schmidt - University Eye Clinic of Tuebingen

Retinologische Gesellschaft. 22. Jahrestagung der Retinologischen Gesellschaft. Berlin, 26.-27.06.2009. Düsseldorf: German Medical Science GMS Publishing House; 2009. DocRG2009-22

DOI: 10.3205/09rg23, URN: urn:nbn:de:0183-09rg231

Published: June 29, 2009

© 2009 Tatar et al.
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by-nc-nd/3.0/deed.en). You are free: to Share – to copy, distribute and transmit the work, provided the original author and source are credited.


Outline

Text

Objective: To evaluate the early effects of triamcinolone acetonide (TA) as either monotherapy or adjuvant to verteporfin photodynamic therapy (PDT) on expression of matrix metalloproteinases (MMP) -2, -9 and endostatin in human choroidal neovascularization (CNV) secondary to age related macular degeneration.

Methods: Retrospective review of interventional series of 38 patients who underwent CNV extraction. Eleven patients were treated with either intravitreal TA (4 mg) monotherapy (TA CNV, n=5) or PDT-TA combination therapy (PDT-TA CNV, n=6) 3 to 9 days preoperatively. Twenty-three CNV without previous therapy (control CNV) and 4 CNV excised 3 days after PDT (PDT CNV) were used as control. CNV were stained for cytokeratin18, CD34, MMP-2 and MMP-9.

Results: MMP-2 and MMP-9 expression in TA CNV was comparable to control CNV. MMP-9 and endostatin expression was significantly weaker in PDT CNV than control CNV (p=0.001; p=0.0035, respectively), TA CNV (p=0.012; p=0.0005, respectively) and PDT-TA CNV (p=0.002; p=0.0001, respectively). MMP-2 and endostatin expression in PDT-TA CNV was stronger than both PDT CNV (p<0.001; p=0.0001, respectively) and control CNV (p=0.001, p=0.02, respectively).

Conclusions: TA probably does not suppress MMP-2 or MMP-9 expression in CNV. PDT induces an early decrease in MMP-9 and endostatin expression. Administration of TA as adjuvant to PDT seems to induce MMP-2 expression and inhibit the decrease in MMP-9 expression after PDT. This correlates with enhanced endostatin expression in PDT-TA CNV.